BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this work, we characterized the miRNome of LSC-enriched CD34+CD38−CD26+ fraction (BCR-ABL1+) and its BCR-ABL1− counterpart (CD34+CD38−CD26− fraction, defined as “CML-CP HSC” in this article) isolated by fluorescence-activated cell sorting (FACS) from CML-CP patients at diagnosis by small RNA-Next-Generation Sequencing (NGS), in order to identify differential molecular mechanisms that contribute to unravel LSC biology, and the possible therapeutic implications of such differences.